Publications by authors named "Mikhail Shkolnik"

Claim this Profile
I
IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Brian I Rini, Arnulf Stenzl, Romauld Zdrojowy, Mikhail Kogan, Mikhail Shkolnik

Lancet Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.
Kenneth J Pienta, Jean-Pascal Machiels, Dirk Schrijvers, Boris Alekseev, Mikhail Shkolnik

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis